Cytosorbents Corp. Files 8-K with Regulatory Updates
Ticker: CTSO · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-update
TL;DR
Cytosorbents Corp. filed an 8-K on 9/16/25 covering Reg FD, other events, and financials.
AI Summary
Cytosorbents Corp. filed an 8-K on September 16, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC, is incorporated in Delaware and headquartered in Princeton, NJ.
Why It Matters
This 8-K filing provides important updates and disclosures from Cytosorbents Corp. to investors and the public, covering regulatory, operational, and financial information.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and disclosures, not indicating immediate financial distress or significant new risks.
Key Numbers
- 001-36792 — SEC File Number (Identifies the company's filing with the SEC.)
- 98-0373793 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cytosorbents Corp. (company) — Registrant
- MedaSorb Technologies CORP (company) — Former Company Name
- GILDER ENTERPRISES INC (company) — Former Company Name
- September 16, 2025 (date) — Date of Report
- 001-36792 (other) — SEC File Number
- 98-0373793 (other) — IRS Employer Identification No.
- 305 COLLEGE ROAD EAST PRINCETON , New Jersey 08540 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for Cytosorbents Corp. and covers Regulation FD Disclosures, Other Events, and Financial Statements and Exhibits, filed on September 16, 2025.
When was Cytosorbents Corp. incorporated, and where is its principal executive office located?
Cytosorbents Corp. is incorporated in Delaware, and its principal executive offices are located at 305 College Road East, Princeton, New Jersey 08540.
What were Cytosorbents Corp.'s former company names?
Cytosorbents Corp. was formerly known as MedaSorb Technologies CORP (name change effective August 7, 2006) and GILDER ENTERPRISES INC (name change effective June 11, 2002).
What is the SEC file number and IRS Employer Identification Number for Cytosorbents Corp.?
The SEC file number for Cytosorbents Corp. is 001-36792, and its IRS Employer Identification Number is 98-0373793.
What items are specifically mentioned as being included in this 8-K filing?
The filing explicitly lists 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits' as items included in this 8-K.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-16 16:35:38
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NASDAQ Check the appropri
Filing Documents
- a8k.htm (8-K) — 25KB
- exhbit99-1.htm (EX-99) — 20KB
- image00001.jpg (GRAPHIC) — 11KB
- 0000929638-25-003494.txt ( ) — 184KB
- ctso-20250916.xsd (EX-101.SCH) — 4KB
- ctso-20250916_lab.xml (EX-101.LAB) — 21KB
- ctso-20250916_pre.xml (EX-101.PRE) — 16KB
- a8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On September 16, 2025, CytoSorbents Corporation (the "Company") issued a press release providing a regulatory update on DrugSorb TM -ATR. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 8.01 Other Events. The information set forth under "Item 7.01 Regulation FD Disclosure" of this Current Report on Form 8-K is incorporated into this Item 8.01 by reference.
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated September 16, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 16, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer